Evidence map›Paper›PMID 42842018›Full record

ReviewActa neuropathologica2026

From a prion seed to a tree of discoveries: Byron Caughey's RT-QuIC legacy in protein misfolding research.

Bradley R Groveman, Sarah Vascellari, Matilde Bongianni, Andrew G Hughson, Gianluigi Zanusso, Christina D Orrú

Abstract readReviewHistorical Article
PubMed Publisher
In one paragraph

Review in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bradley R GrovemanLaboratory of Neurological Infections and Immunity, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Sarah VascellariDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
Matilde BongianniDepartment of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Andrew G HughsonLaboratory of Neurological Infections and Immunity, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Gianluigi ZanussoDepartment of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. gianluigi.zanusso@univr.it.
Christina D OrrúLaboratory of Neurological Infections and Immunity, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. christina.orru@nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early and accurate detection of prions is essential for effective disease management and potential therapeutic intervention. Similar challenges extend across other protein misfolding diseases, which require ultrasensitive methods for detection, discrimination, and quantification of "prion-like" pathological proteins. Over a scientific career spanning multiple decades, Dr. Byron Caughey investigated mechanisms of prion conversion and replication, pioneered cell-free prion conversion assays, and steadfastly pursued increasingly sensitive, specific, robust, and high-throughput methods for prion amplification. His breakthrough development and continued refinement of the Real-Time Quaking-Induced Conversion (RT-QuIC) assay revolutionized prion research and helped extend seed amplification technology across the broader field of protein misfolding diseases. These assays have been developed through seminal contributions by many eminent scientists, and the breadth of this rapidly expanding field extends well beyond the scope of this review. Accordingly, we focus here on honoring Dr. Byron Caughey's legacy by highlighting his foundational contributions to in vitro amplification and ultrasensitive detection of disease-associated protein aggregates. We further highlight the visionary, multidisciplinary, and collaborative nature of his work including the expansion of the platform to strain discrimination, surveillance, misfolded protein quantification, therapeutic research, higher throughput assay formats and the detection of other disease-associated misfolded proteins, including α-synuclein, tau, SOD1, and more.

Indexed as

Prion DiseasesPrionsProteostasis DeficienciesAnimalsHistory, 20th CenturyHistory, 21st CenturyHumansProtein FoldingPrionsAlpha-synucleinDiagnosisPrionRT-QuICSAATau

Identifiers

PMID42842018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.